Series A funding will enable the immediate commercialisation of DARC as an exploratory biomarker for use in clinical trials in the field of glaucoma and AMD.

Our future plans include the continued development of DARC as a diagnostic, following a successful Phase III study. 

If you are interested in receiving further information regarding the Series A investment process and status please register your details below:


 
 

WANT TO GET INVOLVED?

Get in touch for more information
or email:

contact@illustratum.net

Name *
Name